加科思药业
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab 2022-10-13 09:00
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China 2022-09-06 15:20
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China 2022-09-02 19:00
Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China 2022-09-02 17:14
Jacobio Pharma Announces 2022 Interim Results 2022-08-24 00:32
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting 2022-05-28 00:22
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83% 2022-03-22 22:50
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China 2022-02-24 10:32
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA 2022-01-17 09:04
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China 2021-12-06 09:16
Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy 2021-08-31 22:05
Jacobio Pharmaceuticals Announces 2021 Interim Results 2021-08-31 22:01
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor 2021-08-03 09:00
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment 2021-06-18 08:31
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor 2021-05-03 09:30
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results 2021-03-29 13:11
1 2